Clinical Trials Logo

Filter by:
NCT ID: NCT05609292 Completed - Hypothermia Clinical Trials

Testing A Visual Thermometer in Newborns and Young Infants

Start date: December 5, 2022
Phase:
Study type: Observational

"Severe neonatal jaundice and acute bilirubin encephalopathy are a major cause of death and disability among newborns in LMICs. Filtered sunlight phototherapy (FSPT) was developed, tested and shown to be safe and efficacious in the treatment of jaundice, because effective electric-powered conventional phototherapy is often unavailable10,11. However, FSPT currently requires at least hourly temperature monitoring by healthcare providers (HCPs) because infants receiving FSPT are prone to both hypothermia and hyperthermia. 20 years ago, a liquid crystal thermometer, ThermospotTM (Maternova, Providence, RI) was developed primarily for use in LMICs. It was designed to detect hypothermia and is most sensitive in cold infants and not as sensitive as needed for detecting hyperthermia or fever. The purpose of this pilot study is to determine the accuracy and useability of this LCTD for a wider spectrum of temperatures when used in a large group of infants in a high-income country. If the device performs well in this study, we plan to study it in a low- and middle-income country in Africa."

NCT ID: NCT05608915 Completed - Parkinson Disease Clinical Trials

External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait

ELIMINATE-FOG
Start date: November 17, 2022
Phase: N/A
Study type: Interventional

Postural instability, freezing-of-gait (FOG), and falls are among the greatest unmet needs in Parkinson disease (PD). FOG eventually affects more than half of people with PD, and is notoriously difficult to treat pharmacologically or via deep brain stimulation. Visual cues do improve gait freezing, but their efficacy and adoption is limited because they are not practical to use in all real-world situations. There is a need for a cueing technique that is on-demand and discreet - only perceptible to the patient. Fortunately, recent technological advances in augmented-reality (AR) enable such an approach. In this study, state-of-the-art AR glasses will be used to project digital cues that are only visible to the wearer, to determine if they can improve FOG. 36 individuals with PD and FOG will be recruited to perform an obstacle-course gait task under six cue conditions: no cue, conventional cue, constant-on AR, patient-hand-triggered AR (turns on when patient clicks button), patient-eye-triggered AR (turns on when looking down), and examiner-triggered AR. The AR cue is a set of images that appear on the floor at a patient's feet, mimicking floor lines. Gait performance will be captured on video and via body-worn wireless sensors that detect how each limb is moving. The investigators will determine whether individuals are cue-able with conventional visual cues, whether intermittent cues outperform constant-on cues, and whether cues triggered by an examiner outperform cues triggered by patients themselves.

NCT ID: NCT05608629 Completed - Long COVID Clinical Trials

Vagus Nerve Stimulation as Treatment for Long Covid

Start date: June 6, 2022
Phase: N/A
Study type: Interventional

Many patients do not recover following Covid infection. The resulting illness is called Long Covid. Because there is no agreed upon treatment for this ailment, the research team has decided to do an open label pilot study using non-invasive, transcutaneous stimulation of the auricular branch of the vagus nerve. Inclusion criteria required the patient to fulfill criteria for having chronic fatigue syndrome. To date, fourteen patients provided evaluable data. Eight of these fulfilled the study's requirements for treatment success.

NCT ID: NCT05608382 Completed - Clinical trials for Skin Diseases, Infectious

Effect of an Antiseptic Solution on the Skin Microbiome

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

The objective of this study is simulate the clinical use of an antiseptic solution in a 24 hour window and the recovery to baseline conditions at 1 month following application. Efficacy will be simulated as the capacity of the material to reduce or clear the skin bacterial population from a representative skin area: the anteromedial forearm.

NCT ID: NCT05608343 Completed - Atopic Dermatitis Clinical Trials

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Start date: October 1, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic dermatitis.

NCT ID: NCT05608005 Completed - Healthy Volunteers Clinical Trials

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Start date: November 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to Panblok H7 (dose 3) unadjuvanted in approximately 700 adult participants in order to select one dose formulation to be used for further clinical development. The randomization ratio will be 3:3:1 for Panblok H7 (dose 1) + MF59, Panblok H7 (dose 2) + MF59, and Panblok H7 (dose 3) unadjuvanted, respectively. Each study group will be stratified into the age groups 18-64 years and ≥ 65 years of age. The study duration for each participant will be approximately 13 months.

NCT ID: NCT05607784 Completed - Adolescent Behavior Clinical Trials

Education Program to Reduce Risky Behavior in Adolescents Ph I

iTRAC
Start date: November 28, 2022
Phase:
Study type: Observational

This phase will complete the TRAC adaptation to a web app. The pilot study (R21 HD089979) effectively translated the ER content of TRAC and the same procedures will be used to translate the remaining content.

NCT ID: NCT05607277 Completed - Clinical trials for Abdominal Aortic Aneurysm

Global Iliac Branch Study

GIBS
Start date: November 2014
Phase:
Study type: Observational

This project seeks to determine if certain anatomic factors, specifically tortuous and non-conformable iliac arteries, may predict device complications, including seal zone failure, type III endoleak, and occlusion. Approximately 400 subjects from 5 academic centers across the United States, Europe, and Asia will be included in this study. Various markers of pre- and post-treatment iliac anatomy will be measured using CT imaging, and clinical events will be reported by academic centers. The relationship of imaging data to patient demographics will then be assessed alongside anatomic and demographic predictors of non-conformability.

NCT ID: NCT05607212 Completed - Muscle Weakness Clinical Trials

Lumbosacral Muscle Sensitivity & Pressure Pain Threshold After Kettlebell Swings

Start date: November 14, 2022
Phase: N/A
Study type: Interventional

The primary purpose of the study is to assess the muscle contractility and sensitivity of lumbar erector spinae, biceps femoris, and gluteus maximus short-term response to Tabata kettlebell swing protocol.

NCT ID: NCT05607147 Completed - SARS-CoV2 Infection Clinical Trials

Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing

PREDICT-DHCW
Start date: January 26, 2021
Phase: N/A
Study type: Interventional

10 asymptomatic DHCWs in the Oral Medicine clinic, Rutgers School of Dental Medicine, with no history of documented COVID-19 infection or viral exposure, were enrolled in a study that interrogated DHCWs' perceptions of safety and adoption of risk mitigation behavior. Following a baseline survey, finger-prick blood samples were collected twice two weeks apart using an innovative microsampling technique that replaces the need for venipuncture. Samples were processed using an in-house ELISA assay to detect IgM and IgG directed against the Receptor Binding Domain (RBD) of the Spike protein. Weekly Rapid Antigen testing of nasal swab specimens was used to document Antigen negativity during the study.